[NICE Consultation] Brain tumours (primary) and brain metastases in adults

NICE |  March 2020 | Brain tumours (primary) and brain metastases in adults | In development [GID-QS10092]

NICE has released a consultation for the 5 key areas for quality improvement which you consider as having the greatest potential to improve the quality of care in this area. 

Closing date for comments: Monday 20 April 2020 at 5pm

Full details from NICE

NICE Consultation: Selective internal radiation therapies for treating hepatocellular carcinoma ID1276

 NICE |  December  2019 | Selective internal radiation therapies for treating hepatocellular carcinoma ID1276 In development [GID-TA10381]

The Department of Health and Social Care has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using selective internal radiation therapies (SIRT) for treating hepatocellular carcinoma in the NHS in England.

Full details are available from NICE 

The consultation closes on 8 January 2020

NICE: Rezum for treating benign prostatic hyperplasia

NICE |  December  2019 | Rezum for treating benign prostatic hyperplasia

The NICE medical technologies advisory committee (MTAC) has made draft recommendations on this technology following consideration of the evidence and expert views at a meeting on 15th November, 2019

NICE is now seeking feedback, the consultation is open until 8 Jan 2020.

Full details from NICE 

 

[NICE Appraisal consultation] Approval for treatment option for early breast cancer after adjuvant trastuzumab [ID981]

NICE | August 2019| Approval for treatment option for early breast cancer after adjuvant trastuzumab [ID981]

Today (7 August 2019) The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending neratinib as an additional treatment for some people with early hormone- receptor-positive human epidermal growth factor receptor 2 (HER2)- positive breast cancer. 

In a press release, NICE recommends Neratinib (also called Nerlynx and marketed by Pierre Fabre), under the terms of a commercial arrangement, for people with this type of breast cancer who are less than 1 year from completing trastuzumab (Herceptin)-based treatment following surgery (called adjuvant treatment).

The clinical trial evidence showed that people who had treatment with neratinib have less risk of disease recurrence than people who had treatment with a placebo. Despite there being no available data about how this might translate into increasing the overall length of time people live, the committee concluded that the cost-effectiveness estimates for neratinib made it an acceptable use of NHS resources.

Meindert Boysen, director of the Centre for Health Technology Evaluation at NICE, said: “Breast cancer remains the most common form of cancer in the UK, accounting for around 30% of all cancers in women. And although there have been advances in the treatment of early stage HER2-positive breast cancer, around a quarter of people treated with trastuzumab following surgery will have a recurrence of their cancer.

“We are therefore pleased to be able to recommend neratinib as a further treatment option for people with this type of breast cancer, based on the benefits it provides in extending the time before the disease gets worse and on its important potential to reduce the risk of the cancer returning.”

Neratinib, which is taken as 6 x 40 mg tablets daily for 1 year, is recommended provided trastuzumab is the only HER2-directed adjuvant treatment people have had (Source: NICE).

The guidance is in development, comments can be made via the  Appraisal consultation

The closing date for comments is Wednesday 28 August 2019

Related:

NICE [press release] NICE recommends additional treatment option for people with early breast cancer   NICE

See also:

OnMedica Approval for treatment option for early breast cancer 

 

 

NICE Consultation: Lenvatinib for untreated advanced hepatocellular carcinoma

Pancreatic cancer: Quality standard consultation

NICE | July 2018 | Pancreatic cancer: Quality standard consultation

The draft quality standard for Pancreatic cancer is now open for comment

Consultation documents

Briefing paper NICE have written a briefing paper which includes a brief description of the topic, a summary of each of the suggested quality improvement areas and supporting information.

The consultation is open until 5pm on Thursday 16 August 2018

Full details of the standard and how to comment are available from NICE